Roneparstat Melphalan Synergy Multiple Myeloma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma, particularly for relapsed and refractory cases, lack effective and safe therapies, leading to poor prognosis and limited options due to resistance and co-morbid conditions.
Innovation Solution
The combination of roneparstat, a modified heparin derivative, with melphalan for use in a combined therapy to treat multiple myeloma, demonstrating synergism in reducing tumor burden through co-administration or sequential supplementation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy or high-dose chemotherapy is used to treat multiple myeloma, then initial response may be achieved, but resistance develops and the disease becomes refractory with poor prognosis
Solution Approach 1:
The patent combines roneparstat with melphalan to create a synergistic combination therapy. This merging of two different therapeutic agents addresses the resistance problem by attacking the cancer cells through multiple mechanisms simultaneously, thereby improving treatment effectiveness and extending survival time in relapsed and refractory multiple myeloma patients
Solution Approach 2:
The patent employs a composite therapeutic approach by combining roneparstat (a modified heparin derivative with anticoagulant and antiproliferative properties) with melphalan (an alkylating agent). This composite therapy leverages the complementary mechanisms of action of both drugs to overcome resistance and improve outcomes where single-agent therapies have failed
2Reliability
If multiple novel agents are used to treat relapsed myeloma, then response rates improve, but treatment options are limited due to co-morbid conditions from prior therapies
Solution Approach 1:
The patent introduces roneparstat, a novel agent with a different mechanism of action compared to previously used therapies. This parameter change in therapeutic approach provides new treatment flexibility for patients who have exhausted standard options, allowing treatment of relapsed myeloma without being constrained by prior therapy-related co-morbidities
3Reliability
If bortezomib is used as induction therapy before ASCT, then overall response rate and progression-free survival improve, but the disease remains incurable and relapse occurs
Solution Approach 1:
The patent uses roneparstat in combination with melphalan as induction therapy before autologous stem cell transplantation (ASCT). This preliminary action aims to achieve deeper and more durable responses by reducing tumor burden more effectively, thereby extending the disease-free period and potentially preventing relapse in high-risk patients
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to roneparstat for use in a combined therapy for the treatment of multiple myeloma. In particular it has unexpectedly been found that the combined use of roneparstat with a proteasome inhibitor, in particular selected between bortezomib and carfilzomib or with melphalan improve efficacy in decreasing the overall tumor burden, especially showing synergism, with respect to the administration of each active ingredient alone.